These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 25024336)

  • 1. Increased levels of hyaluronic acid in cerebrospinal fluid in patients with vascular dementia.
    Nägga K; Hansson O; van Westen D; Minthon L; Wennström M
    J Alzheimers Dis; 2014; 42(4):1435-41. PubMed ID: 25024336
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of CSF biomarkers in the diagnostic work-up of mixed vascular-degenerative dementia.
    Engelborghs S; Le Bastard N
    J Neurol Sci; 2012 Nov; 322(1-2):197-9. PubMed ID: 22947896
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cerebrospinal fluid levels of heart fatty acid binding protein are elevated prodromally in Alzheimer's disease and vascular dementia.
    Olsson B; Hertze J; Ohlsson M; Nägga K; Höglund K; Basun H; Annas P; Lannfelt L; Andreasen N; Minthon L; Zetterberg H; Blennow K; Hansson O
    J Alzheimers Dis; 2013; 34(3):673-9. PubMed ID: 23254629
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cerebrospinal fluid matrix metalloproteinases and tissue inhibitor of metalloproteinases in combination with subcortical and cortical biomarkers in vascular dementia and Alzheimer's disease.
    Bjerke M; Zetterberg H; Edman Å; Blennow K; Wallin A; Andreasson U
    J Alzheimers Dis; 2011; 27(3):665-76. PubMed ID: 21860087
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of cerebrospinal fluid (CSF) beta-amyloid (1-42), phosphorylated tau (ptau-181) and total Tau protein in patients with Alzheimer's disease (AD) and other dementia at Siriraj Hospital, Thailand.
    Thaweepoksomboon J; Senanarong V; Poungvarin N; Chakorn T; Siwasariyanon N; Washirutmangkur L; Udompunthuruk S
    J Med Assoc Thai; 2011 Feb; 94 Suppl 1():S77-83. PubMed ID: 21721431
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blood-based neurochemical diagnosis of vascular dementia: a pilot study.
    Bibl M; Esselmann H; Mollenhauer B; Weniger G; Welge V; Liess M; Lewczuk P; Otto M; Schulz JB; Trenkwalder C; Kornhuber J; Wiltfang J
    J Neurochem; 2007 Oct; 103(2):467-74. PubMed ID: 17662050
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Associations between cerebral small-vessel disease and Alzheimer disease pathology as measured by cerebrospinal fluid biomarkers.
    Kester MI; Goos JD; Teunissen CE; Benedictus MR; Bouwman FH; Wattjes MP; Barkhof F; Scheltens P; van der Flier WM
    JAMA Neurol; 2014 Jul; 71(7):855-62. PubMed ID: 24818585
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The neurofilament heavy chain (NfH) in the cerebrospinal fluid diagnosis of Alzheimer's disease.
    Brettschneider J; Petzold A; Schottle D; Claus A; Riepe M; Tumani H
    Dement Geriatr Cogn Disord; 2006; 21(5-6):291-5. PubMed ID: 16484807
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Microbleeds relate to altered amyloid-β metabolism in Alzheimer's disease.
    Goos JD; Teunissen CE; Veerhuis R; Verwey NA; Barkhof F; Blankenstein MA; Scheltens P; van der Flier WM
    Neurobiol Aging; 2012 May; 33(5):1011.e1-9. PubMed ID: 22118945
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cerebrospinal fluid Aβ1-40 improves differential dementia diagnosis in patients with intermediate P-tau181P levels.
    Slaets S; Le Bastard N; Martin JJ; Sleegers K; Van Broeckhoven C; De Deyn PP; Engelborghs S
    J Alzheimers Dis; 2013; 36(4):759-67. PubMed ID: 23666174
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cerebrospinal fluid markers in differential diagnosis of Alzheimer's disease and vascular dementia.
    Boban M; Grbić K; Mladinov M; Hof PR; Süssmair C; Ackl N; Stanić G; Bader B; Danek A; Simić G
    Coll Antropol; 2008 Jan; 32 Suppl 1():31-6. PubMed ID: 18405055
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Flotillin is a Novel Diagnostic Blood Marker of Alzheimer's Disease.
    Abdullah M; Kimura N; Akatsu H; Hashizume Y; Ferdous T; Tachita T; Iida S; Zou K; Matsubara E; Michikawa M
    J Alzheimers Dis; 2019; 72(4):1165-1176. PubMed ID: 31683489
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CSF levels of the neuronal injury biomarker visinin-like protein-1 in Alzheimer's disease and dementia with Lewy bodies.
    Luo X; Hou L; Shi H; Zhong X; Zhang Y; Zheng D; Tan Y; Hu G; Mu N; Chan J; Chen X; Fang Y; Wu F; He H; Ning Y
    J Neurochem; 2013 Dec; 127(5):681-90. PubMed ID: 23800322
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cerebrospinal fluid markers of pathogenetic processes in vascular dementia, with special reference to the subcortical subtype.
    Wallin A; Blennow K; Rosengren L
    Alzheimer Dis Assoc Disord; 1999; 13 Suppl 3():S102-5. PubMed ID: 10609688
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical indications for analysis of Alzheimer's disease CSF biomarkers.
    Engelborghs S
    Rev Neurol (Paris); 2013 Oct; 169(10):709-14. PubMed ID: 24016466
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain.
    Tapiola T; Alafuzoff I; Herukka SK; Parkkinen L; Hartikainen P; Soininen H; Pirttilä T
    Arch Neurol; 2009 Mar; 66(3):382-9. PubMed ID: 19273758
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of selenium, redox status and their association with plasma amyloid/tau in Alzheimer's disease.
    Krishnan S; Rani P
    Biol Trace Elem Res; 2014 May; 158(2):158-65. PubMed ID: 24682919
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased CSF α-synuclein levels in Alzheimer's disease: correlation with tau levels.
    Slaets S; Vanmechelen E; Le Bastard N; Decraemer H; Vandijck M; Martin JJ; De Deyn PP; Engelborghs S
    Alzheimers Dement; 2014 Oct; 10(5 Suppl):S290-8. PubMed ID: 24439167
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low cerebrospinal fluid sulfatide predicts progression of white matter lesions: The LADIS study.
    Jonsson M; Zetterberg H; Rolstad S; Edman A; Gouw AA; Bjerke M; Lind K; Blennow K; Pantoni L; Inzitari D; Wallin A
    Dement Geriatr Cogn Disord; 2012; 34(1):61-7. PubMed ID: 22922641
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study.
    Hampel H; Buerger K; Zinkowski R; Teipel SJ; Goernitz A; Andreasen N; Sjoegren M; DeBernardis J; Kerkman D; Ishiguro K; Ohno H; Vanmechelen E; Vanderstichele H; McCulloch C; Moller HJ; Davies P; Blennow K
    Arch Gen Psychiatry; 2004 Jan; 61(1):95-102. PubMed ID: 14706948
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.